IDH mutations have been implicated in other cancer types, including AML, myelodysplastic syndrome (15–18), cholangiocarcinoma of intrahepatic origin (53), central and periosteal cartilaginous chondrosarcomas (54), and melanoma (55, 56). This evidence concerns the gene IDH2 and acute myeloid leukemia.